What This Bill Does
This bill would require health insurance coverage for drugs used to treat autoimmune diseases and certain blood disorders under ERISA-covered plans, the Public Health Service Act, and the Internal Revenue Code. In practical terms, it would push many employer plans and individual market plans to cover these medications when they are medically indicated. The measure is aimed at patients who rely on specialty drugs for chronic, often serious conditions, and it would standardize coverage across major categories of private insurance. Because the bill is written as a coverage mandate, its main effect would be on insurers, employers that sponsor health plans, and patients facing high out-of-pocket costs or denials.
- Requires coverage of drugs indicated for autoimmune diseases and certain blood disorders
- Applies to ERISA health plans, Public Health Service Act plans, and tax-related health coverage rules
- Would affect employer-sponsored insurance and many other private health plans
- Targets medically indicated drugs used for chronic specialty treatment
Who This Bill Affects
If you or someone in your household has an autoimmune disease or a qualifying blood disorder, this bill could make it easier to get insurance coverage for prescribed drugs used to treat those conditions. That could mean fewer denials, less uncertainty about whether a specialty medication is covered, and potentially lower out-of-pocket costs if the plan must include the drug. For people without those conditions, the main effect would be indirect through possible changes in premiums or plan design.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients with autoimmune diseases These patients often depend on specialty drugs to control symptoms and prevent serious complications. A coverage mandate can reduce denials and make treatment more predictable and affordable.
- Families managing chronic blood disorders Long-term therapy can be financially overwhelming when a plan excludes a needed drug. Requiring coverage helps families avoid treatment interruptions and large unexpected bills.
- Health care providers treating complex chronic conditions Clinicians want to prescribe the most effective therapy without insurance barriers getting in the way. Broader coverage can improve adherence and reduce avoidable disease flare-ups or hospitalizations.
- Health insurers A federal coverage mandate limits plan flexibility and can force coverage of high-cost specialty drugs regardless of a plan’s existing formulary strategy. Insurers may argue this raises premiums and reduces their ability to manage costs.
- Employers that sponsor health plans If the mandate increases drug spending, employers may face higher benefit costs and administrative changes. Some may worry that those costs will be passed on through lower wages or higher employee contributions.
- Cost-conscious purchasers and plan administrators They may support access goals but oppose one-size-fits-all coverage rules that override benefit design. Their concern is that mandated coverage can reduce bargaining power and complicate utilization management.
Key Implications
-
““require health insurance coverage of drugs indicated for the treatment of autoimmune diseases””
This would make coverage for qualifying autoimmune-disease drugs a federal requirement in the affected insurance systems, reducing the chance that a plan can exclude them outright.
-
““and certain blood disorders””
The mandate is not limited to autoimmune conditions; it also extends to some blood-disorder treatments, broadening the group of patients who could benefit.
-
““amend the Employee Retirement Income Security Act of 1974””
ERISA coverage rules matter because many Americans get insurance through employers, so this is the channel most likely to affect job-based plans.
-
““title XXVII of the Public Health Service Act””
This ties the mandate to federal health insurance market standards, which can influence how private plans structure covered benefits.
-
““the Internal Revenue Code of 1986””
Including the tax code helps align the mandate with federal rules governing health coverage and employer-sponsored benefits.
Latest Status
June 8, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.